858 Therapeutics Funding: $110M Raised, Series A (2021)
858 Therapeutics is a Biotech company based in San Diego. It has raised $110M in total funding. Latest round: Series A.
858 Therapeutics funding overview
858 Therapeutics is a Biotech company based in San Diego. 858 Therapeutics has raised $110M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in September 2021. The round record for 858 Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include Versant Ventures, NEA, Cormorant Asset Management, Logos Capital, Avidity Partners. 5 distinct backers are named across the disclosed rounds.
858 Therapeutics has raised $110M in total disclosed funding across the rounds on record.
Who has invested in 858 Therapeutics?
Versant Ventures, NEA, Cormorant Asset Management, Logos Capital, Avidity Partners are named among the investors backing 858 Therapeutics.
What was the latest 858 Therapeutics funding round?
The most recent disclosed round is a Series A, announced in September 2021.
Where is 858 Therapeutics based?
858 Therapeutics is based in San Diego.
What sector does 858 Therapeutics operate in?
858 Therapeutics is tracked under Biotech from San Diego, with $110M in disclosed funding.
When did 858 Therapeutics last raise?
The last disclosed 858 Therapeutics round closed in September 2021 at Series A.
We update the 858 Therapeutics record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related Biotech companies in San Diego and their backers are listed below.
